Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril

Clinical and Experimental Pharmacology and Physiology

Volumn 30, Issue 10, 2003, Pages 779-785

  Fonseca, F A H ^a   Ihara, S S M ^a   Izar, M C O ^a   Silva, E P ^a   Kasinski, N ^a   Lopes, I E L ^a   Pinto, L E S A ^a   Paiva, T B ^a   Tufik, S ^a   De Paola, A A V ^a   Carvalho, A C C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antihypertensive agents; Atherosclerosis; Endothelium; Hypercholesterolaemia; Rabbits

Indexed keywords

CHOLESTEROL; CLORANA; ELECTROLYTE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINAPRIL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY RISK; DOSE TIME EFFECT RELATION; DRUG CROSS REACTIVITY; ELECTROLYTE BLOOD LEVEL; HYPERTENSION; HYPOTHESIS; INTIMA; LIPID ANALYSIS; MALE; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; RABBIT; RANDOMIZATION; STATISTICAL SIGNIFICANCE; STROKE; VASCULAR RING; VASODILATATION;

ANIMALS; AORTA, THORACIC; ARTERIOSCLEROSIS; CHOLESTEROL; DRUG INTERACTIONS; HYDROCHLOROTHIAZIDE; MALE; RABBITS; TETRAHYDROISOQUINOLINES; VASODILATION;

EID: 10744221087     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2003.03911.x     Document Type: Article

References (37)

1. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part II. Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
2. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997; 277: 739-45.
3. MacMahon S, Peto R, Cutler J et al. J. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 764-74.
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 355: 1575-81.
5. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
6. Hernandez-Presa M, Bustos C, Ortego M et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-41.
7. Pitt B. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am. Heart J. 1994; 128: 1328-32.
8. Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am. J. Physiol. 1996; 271: H1065-71.
9. Hoshida S, Nishida M, Yamashita N et al. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: Effects of enalapril. Atherosclerosis 1997; 130: 53-9.
10. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-κB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am. J. Pathol. 1998; 153: 1825-37.
11. Rubanyi G. The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Pharmacol. 1993; 22 (Suppl. 4): S1-14.
12. Cooke JP, Tsao PS. Endothelial alterations in atherosclerosis: The role of nitric oxide. In: Webb D, Wallance P (eds). Endothelial Function in Hypertension. Springer-Verlag, Heidelberg. 1997; Ch. 3.
13. Anonymous. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch. Intern. Med. 1997; 157: 2413-45.
14. Silva EP, Fonseca FA, Ihara SS et al. Early benefits of pravastatin to experimentally induced atherosclerosis. J. Cardiovasc. Pharmacol. 2002; 39: 389-95.
15. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Wolff SP. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal. Biochem. 1994; 220: 403-9.
16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979; 95: 351-8.
17. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Circulation 1990; 81: 1762-7.
18. Taddei S, Virdis A, Mattei P, Salvetti A. A vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 87: 1468-74.
19. G-monomethyl-L-arginine in patients with hypertension: The nitric oxide dilator mechanism appears abnormal. J. Hypertens. 1992; 10: 1025-31.
20. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence for the abnormality is not at the muscarinic receptor level. J. Am. Coll. Cardiol. 1994; 23: 1610-16.
21. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon 3rd RO, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilatation in patients with essential hypertension, Circulation 1998; 97: 851-6.
22. Minor Jr RL, Myers PR, Guerra Jr R, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J. Clin. Invest. 1990; 86: 2109-16.
23. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J. Biol. Chem. 1995; 270: 17 050-5.
24. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 1993; 91: 2546-51.
25. Schalekamp MA. Second Bjorn Folkow Award Lecture. The renin-angiotensin system: New surprises ahead. J. Hypertens. 1991; 9 (Suppl. 6): S10-17.
26. Johnston CI. Franz Volhard Lecture. Renin-angiotensin system: A dual tissue and hormonal system for cardiovascular control. J. Hypertens. 1992; 10 (Suppl. 7): S13-26.
27. Mombouli JV, Vanhoutte PM. Kinins mediate kallikrein-induced endothelium-dependent relaxation in isolated canine coronary arteries. Biochem. Biophys. Res. Commun. 1992; 185: 693-7.
28. 2+ uptake in mouse distal convoluted tubule cells. Kidney Int. 1996; 51: 8-17.
29. Good JM, Brady AJ, Noormohamed FH, Oakley CM, Cleland JG. Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation 1994; 90: 220-4.
30. Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition. Mechanistic evidence to support RALES. Circulation 2000; 102: 2325-8.
31. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 679-85.
32. Penschow JD, Bulmer B. Effects of diuretics on renal kallikrein gene expression in rats. Clin. Exp. Pharmacol. Physiol. 1998; 25 (Suppl.): S86-90.
33. Vergely C, Walker MK, Zeller M et al. Antioxidant properties of indapamide, 5-OH indapamide and hydrochlorothiazide evaluated by oxygen-radical absorbing capacity and electron paramagnetic resonance. Mol. Cell. Biochem. 1998; 178: 151-5.
34. Weidmann P. Metabolic profile of indapamide sustained-released in patients with hypertension: Data from three randomized double-blind studies. Drug Safety 2001; 24: 1155-65.
35. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT). JAMA 2002; 288: 2981-97.
36. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 26: 124-30.
37. Rahman M, Douglas JG, Wright Jr JT. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol. Metab. Clin. North Am. 1997; 26: 125-44.